Zymeworks Inc (ZYME)
Zymeworks Inc. is a biotechnology company focused on developing biotherapeutics for cancer, inflammation, and autoimmune diseases. The company’s technology base includes the Azymetric multispecific antibody platform, the Drug Conjugate platform, the EFECT Fc-engineering platform, and the ProTECT tumor-specific immune co-stimulation platform. Its pipeline includes Ziihera (zanidatamab-hrii), a bispecific antibody for HER2-expressing tumors, along with zanidatamab for use in neoadjuvant settings, breast cancer, and other HER2-related cancers. Other development programs include Pasritamig, ZW191, ZW251, ZW220, ZW209, and ZW1528, each aimed at specific oncology or respiratory targets. Zymeworks also maintains strategic collaborations with several pharmaceutical partners, including Jazz Pharmaceuticals, Bristol Myers Squibb, GlaxoSmithKline, Daiichi Sankyo, Merck Sharp & Dohme, and Janssen Biotech. The company was incorporated in 2003 and is based in Middletown, Delaware.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-ZYME
|
$29.53
|
7.1% Upside
|
Fair
|
$41.23
|
49.5% Upside
|
Undervalued
|
Fair
|
0.0%
|
November 10, 2026
|
23.7x
|
51.3x
|
1.956 B
|
1.596 B
|
0.8%
|
92.8%
|
-1.1
|
80.4%
|
